Using varying dosage levels, the oral PCSK9 inhibitor MK-0616 significantly and clinically reduced low-density lipoprotein cholesterol (LDL-C) in patients with hypercholesterolemia and a wide range of atherosclerotic cardiovascular disease (ASCVD) risk and background statin therapy compared to placebo after 8 weeks, new randomized trial results show.